HER2-negative breast cancer Clinical Trials

Recruiting her2-negative breast cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat her2-negative breast cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting her2-negative breast cancer studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting her2-negative breast cancer trials

Within

A Study of the TheraBionic P1 Device in Breast Cancer

for Breast Cancer Stage I

8 sites incl. Clarkston

Sponsor: Barbara Ann Karmanos Cancer Institute

Sex: Female·Age: 22+

Code: NCT07218432

Apply to this trial

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

for Breast Cancer (Early Breast Cancer)

Sponsor: Assistance Publique - Hôpitaux de Paris

Sex: Female·Age: 18+

Code: NCT07379918

Apply to this trial

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

for Advanced Breast Cancer

Sponsor: Zhejiang Cancer Hospital

Sex: All·Age: 18+

Code: NCT07602907·Phase 2

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

for Hormone Receptor-Positive Breast Cancer

Sponsor: Peking University People's Hospital

Sex: Female·Age: 18 - 75

Code: NCT07366112·Phase 2

Apply to this trial

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

for HER2-negative Breast Cancer

Sponsor: Fudan University

Sex: Female·Age: 18+

Code: NCT07466927·Phase 2

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

for Breast Cancer

7 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: Female·Age: 50+

Code: NCT07483307·Phase 2

Apply to this trial

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

for HER2-negative Breast Cancer

Sponsor: Barbara Ann Karmanos Cancer Institute

Sex: All·Age: 22+

Code: NCT07227831

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

for HER2-Negative Breast Cancer

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Sex: Female·Age: 18 - 70

Code: NCT07396454·Phase 2

Apply to this trial

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

for Breast Cancer

Sponsor: West German Study Group

Sex: All·Age: 18+

Code: NCT07281833·Phase 3

Apply to this trial

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

for Metastatic Breast Cancer

1 site in Boston

Sponsor: Kristina A. Fanucci

Sex: All·Age: 18+

Code: NCT07198724·Phase 1, Phase 2

Apply to this trial

Breast Re-irradiation After Second Ipsilateral Lumpectomy

for Breast Cancer

2 sites incl. Boca Raton

Sponsor: Youssef Zeidan

Sex: Female·Age: 40+

Code: NCT06867484

Apply to this trial

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

for HER2-negative Breast Cancer

1 site in San Francisco

Sponsor: University of California, San Francisco

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06774027

Apply to this trial

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

for Hormone Receptor-Positive Breast Cancer

Sponsor: Peking University People's Hospital

Sex: Female·Age: 18 - 75

Code: NCT06970912·Phase 2

Apply to this trial

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

for HER2-negative Breast Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18+

Code: NCT06993506

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

for Triple Negative Breast Cancer

10 sites incl. Denver

Sponsor: Dren Bio

Sex: All·Age: 18+

Code: NCT06999187·Phase 1

Apply to this trial

NearWave Optical Molecular Monitoring

for Breast Cancer

1 site in Indianapolis

Sponsor: Indiana University

Sex: Female·Age: 18+

Code: NCT06744465

Apply to this trial

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

for Hormone-receptor-positive Breast Cancer

3 sites incl. Iowa City

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06756932·Phase 1

Apply to this trial

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

for Early Breast Cancer

Sponsor: Institute of Oncology Ljubljana

Sex: Female·Age: 18 - 99

Code: NCT06650423

Apply to this trial

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

for ER+ Breast Cancer

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT06407401·Phase 3

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

for Advanced Breast Cancer

Sponsor: MedSIR

Sex: All·Age: 18+

Code: NCT06382948·Phase 3

Apply to this trial

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

for Metastatic Breast Cancer

7 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT06678269·Phase 1

Apply to this trial

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

for Breast Cancer Metastatic Breast Cancer

1 site in Tampa

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All·Age: 18+

Code: NCT06691035·Phase 1

Apply to this trial

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

for Hormone Receptor-Positive Breast Cancer

7 sites incl. Elizabeth

Sponsor: Rutgers, The State University of New Jersey

Sex: All·Age: 18+

Code: NCT06518837·Phase 2

Apply to this trial

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

for Breast Cancer

11 sites incl. Birmingham

Sponsor: Ana C Garrido-Castro, MD

Sex: All·Age: 18+

Code: NCT06533826·Phase 2

Apply to this trial

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

for Advanced Breast Cancer

Sponsor: Fudan University

Sex: All·Age: 18+

Code: NCT06649331·Phase 2

Apply to this trial

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

for Breast Cancer

1 site in New Haven

Sponsor: Yale University

Sex: Female·Age: 18+

Code: NCT05989347·Phase 1

Apply to this trial

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

for Breast Cancer

13 sites incl. Tucson

Sponsor: Processa Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06568692·Phase 2

Apply to this trial

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

for HER2-negative Breast Cancer

Sponsor: Guangdong Provincial People's Hospital

Sex: All·Age: 18 - 80

Code: NCT06102824·Phase 2

Apply to this trial

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

for BRCA-Mutated Breast Carcinoma

Sponsor: Fudan University

Sex: Female·Age: 18 - 70

Code: NCT06516289·Phase 2

Apply to this trial

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

for Breast Cancer

3 sites in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06488378·Phase 1

Apply to this trial

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

for HER2-negative Breast Cancer

1 site in Jacksonville

Sponsor: Mayo Clinic

Sex: Female·Age: 18+

Code: NCT06388122

Apply to this trial

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

for Breast Cancer

3 sites incl. Miami

Sponsor: Sarah Sammons, MD

Sex: All·Age: 18+

Code: NCT06176261·Phase 2

Apply to this trial

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

for HER2-negative Breast Cancer

Sponsor: Fudan University

Sex: All·Age: 18+

Code: NCT06230055·Phase 4

Apply to this trial

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

for ER-positive Breast Cancer

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT05512364·Phase 3

Apply to this trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

for Advanced Solid Tumor

8 sites incl. Denver

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06120283·Phase 1

Apply to this trial

PRE-I-SPY Phase I/Ib Oncology Platform Program

for HER2-positive Breast Cancer

7 sites incl. Birmingham

Sponsor: QuantumLeap Healthcare Collaborative

Sex: All·Age: 18+

Code: NCT05868226·Phase 1

Apply to this trial

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

for Breast Cancer

Sponsor: Gangnam Severance Hospital

Sex: Female·Age: 20 - 50

Code: NCT05333328·Phase 4

Apply to this trial

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

for Breast Cancer

Sponsor: SOLTI Breast Cancer Research Group

Sex: Female·Age: 35+

Code: NCT05982093·Phase 2

Apply to this trial

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

for HER2-negative Breast Cancer

3 sites incl. Bethesda

Sponsor: The Methodist Hospital Research Institute

Sex: All·Age: 18+

Code: NCT05660083·Phase 2

Apply to this trial

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

for Breast Neoplasm

Sponsor: Fudan University

Sex: Female·Age: 18+

Code: NCT05594095·Phase 2

Apply to this trial

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

for Breast Neoplasm

Sponsor: Fudan University

Sex: Female·Age: 18 - 70

Code: NCT05582499·Phase 2

Apply to this trial

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

for Breast Cancer

Sponsor: Institut fuer Frauengesundheit

Sex: Female·Age: 18+

Code: NCT05452213·Phase 4

Apply to this trial

Role of the Immune Environment in Response to Therapy in Breast Cancer

for Breast Cancer

1 site in Philadelphia

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female·Age: 18+

Code: NCT05396612

Apply to this trial

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

for Locoregional Recurrence

19 sites incl. Birmingham

Sponsor: Oana Danciu

Sex: All·Age: 18+

Code: NCT05467891·Phase 2

Apply to this trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

for Metastatic Breast Cancer

14 sites incl. Gilbert

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05508906·Phase 1

Apply to this trial

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

for Breast Cancer

1 site in Orange

Sponsor: University of California, Irvine

Sex: All·Age: 18+

Code: NCT05524584·Phase 2

Apply to this trial

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

for Triple Negative Breast Cancer

1 site in Tampa

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All·Age: 18+

Code: NCT05504707·Phase 1

Apply to this trial

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

for HER2-negative Breast Cancer

5 sites incl. Chicago

Sponsor: University of Texas Southwestern Medical Center

Sex: All·Age: 18 - 99

Code: NCT05029999·Phase 1

Apply to this trial

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

for ER+ Breast Cancer

Sponsor: Royal Marsden NHS Foundation Trust

Sex: All·Age: 18+

Code: NCT04985266·Phase 2

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

23 sites incl. Tucson

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1

Apply to this trial

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

for Breast Cancer

1 site in Madison

Sponsor: University of Wisconsin, Madison

Sex: All·Age: 18+

Code: NCT04573231·Phase 2

Apply to this trial

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

for ER-Positive Breast Cancer

1 site in Houston

Sponsor: The Methodist Hospital Research Institute

Sex: All·Age: 18+

Code: NCT05305924·Phase 2

Apply to this trial

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

for Pancreatic Adenocarcinoma Metastatic

1 site in New York

Sponsor: General Oncology, Inc.

Sex: All·Age: 18+

Code: NCT04150042·Phase 1

Apply to this trial

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

for Breast Cancer

Sponsor: Hebei Medical University Fourth Hospital

Sex: Female·Age: 55+·Accepts healthy volunteers

Code: NCT06375798

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

31 sites incl. La Jolla

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2

Apply to this trial

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

for HER2-negative Breast Cancer

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Sex: Female·Age: 18 - 70

Code: NCT04576143·Phase 2, Phase 3

Apply to this trial

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

for Metastatic Breast Cancer

Sponsor: Fondazione Sandro Pitigliani

Sex: Female·Age: All ages

Code: NCT04660435

Apply to this trial

Sacituzumab Govitecan In TNBC

for Invasive Breast Cancer

4 sites incl. Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT04230109·Phase 2

Apply to this trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

for Breast Neoplasms

33 sites incl. Birmingham

Sponsor: QuantumLeap Healthcare Collaborative

Sex: All·Age: 18+

Code: NCT01042379·Phase 2

Apply to this trial

HER2-negative breast cancer clinical trials — common questions

Are her2-negative breast cancer clinical trials free to join?

Yes. Participating in a her2-negative breast cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a her2-negative breast cancer clinical trial?

Each her2-negative breast cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a her2-negative breast cancer trial near me?

Use the location controls above. We'll show recruiting her2-negative breast cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many her2-negative breast cancer trials are recruiting right now?

We're currently tracking roughly 34 recruiting her2-negative breast cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

HER2-negative breast cancer trials by city

Birmingham, AL Boston, MA Denver, CO Tampa, FL Boca Raton, FL Chicago, IL Clarkston, MI Indianapolis, IN Jacksonville, FL La Jolla, CA Madison, WI Miami, FL

Related specialties

Oncology Breast oncology